Document 0192
 DOCN  M95A0192
 TI    Do safety issues of plasma products constrain self-sufficiency?
 DT    9510
 AU    Savidge GF; Haemophilia Reference Centre, Guy's & St Thomas' Hospital
       NHS; Trust, St Thomas' Hospital, London, UK.
 SO    Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S67-70. Unique Identifier
       : AIDSLINE MED/95315447
 AB    The ultimate responsibility for selecting and administering plasma
       products to patients rests with the prescribing physician, and it is for
       him/her to choose the safest product available. However, liability for a
       product with a full licence rests exclusively with the licence holder.
       After the problems of HIV and hepatitis C the safety of plasma-derived
       products has become of paramount importance. Particularly in the public
       sector, financial, strategic and political obstacles may adversely
       influence the quantity, quality and safety of plasma collection. The
       safety of blood products can be substantially enhanced by the
       harmonization of technical standards across both public and private
       sectors, thus supporting EC Directive 89/381. Additionally, the goal of
       European rather than national self-sufficiency should be encouraged.
 DE    Blood Banks/ECONOMICS/LEGISLATION & JURISPRUD/*STANDARDS  Blood Donors
       Blood Proteins/ADVERSE EFFECTS/ISOLATION & PURIF/*SUPPLY &
       DISTRIBUTION/THERAPEUTIC USE  European Economic Community  Factor
       VIII/ADVERSE EFFECTS/SUPPLY & DISTRIBUTION/THERAPEUTIC USE  Fees and
       Charges  Hepatitis C/PREVENTION & CONTROL/TRANSMISSION  Human  HIV
       Infections/PREVENTION & CONTROL/TRANSMISSION  Jurisprudence  Licensure
       *Plasma  Professional Autonomy  *Safety  Voluntary Workers  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).